Related Experiment Videos
Dosage dependent hormonal counter regulation to combination therapy in patients with left ventricular dysfunction.
A M Galløe1, K Skagen, N J Christensen
1Medical Department F, Copenhagen County Hospital in Herlev, Denmark. a.galloe@dadlnet.dk
Journal of Clinical Pharmacy and Therapeutics
|April 26, 2006
Summary
This study found that lower doses of trandolapril and bumetanide may be optimal for heart failure patients. Combination therapy did not show clear benefits, suggesting individualized low-dose treatment for water retention or symptoms.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Combination therapy for heart failure lacks comprehensive dose-response data.
- Existing studies often add single agents to usual care, not exploring optimal combinations.
Purpose of the Study:
- To assess the efficacy of combination therapy for heart failure using trandolapril and bumetanide.
- To determine optimal dosages for combination therapy in heart failure management.
Main Methods:
- A double-blind, randomized, multiple cross-over study with 16 dosage combinations.
- Utilized a 16x6 balanced incomplete Latin square design.
- Evaluated quality of life, left ventricular function, heart rate, plasma noradrenaline, diuresis, weight loss, blood pressure, and renin concentration.
Main Results:
- Optimal quality of life was reported with sub-maximal bumetanide dose.
- Higher bumetanide doses ( > 0.5 mg BID) decreased quality of life and increased diuresis.
- Maximal weight loss occurred at 0.5 mg bumetanide twice daily.
- Trandolapril (0.5 mg daily) maximally reduced systolic blood pressure.
- Both drugs increased renin concentration with potentiating interaction.
- No clear beneficial effects of combination therapies were detected.
Conclusions:
- Lower than usual dosages of trandolapril and bumetanide may be beneficial for heart failure.
- Low-dose loop diuretics can be considered for water retention or symptomatic relief.